Two families of transcription factors, myogenic regulatory factors (MRFs) and myocyte enhancer factor 2 (MEF2), function synergistically to regulate myogenesis. In addition to activating structural muscle-specific genes, MRFs and MEF2 activate each other's expression. The MRF, myogenin, can activate MEF2 DNA binding activity when transfected into fibroblasts and, in turn, the myogenin promoter contains essential MEF2 DNA binding elements. To determine which MEF2 is involved in this regulation, P19 cells stably expressing MyoD and myogenin were compared for their ability to activate the expression of MEF2 family members. There was very little cross-activation of MyoD expression by myogenin and vice versa. Myogenin expression, and not MyoD, was found to up-regulate MEF2C expression. MEF2A, -B, and -D expression levels were not up-regulated by overexpression of either MyoD or myogenin. To examine whether MEF2C can differentially regulate MyoD or myogenin expression, P19 cell lines overexpressing MEF2C were analyzed. MEF2C induced myogenesis in P19 cells and up-regulated the expression of myogenin with 25-fold greater efficiency than that of MyoD. Therefore, myogenin and MEF2C participate in a regulatory loop in differentiating stem cells. This positive regulation does not extend to MyoD or the other MEF2 family members. Consequently, MEF2C appears to play a specific role in early events of myogenesis.
Two families of transcription factors, the MEF2 1 family and the myogenic basic helix-loop-helix family (MRFs), interact to synergistically activate skeletal muscle-specific promoters (1) (2) (3) . The four vertebrate MEF2 family members, MEF2A-D (4, 5) , contain a conserved MCM1, agamous, deficiens, and serum response factor-box/MEF2 domain at their N termini. This domain mediates protein-protein interactions as well as DNA binding to an AT-rich MEF2 binding site. The four MRFs, MyoD, myogenin, myf-5, and MRF4 (6 -12) , bind to E box sequences in the promoters of skeletal muscle-specific genes and can induce skeletal muscle development when expressed in fibroblasts (13) . A positive feedback loop likely exists between MEF2 and myogenin because myogenin induces MEF2 DNA binding activity in various cell lines (14) , and MEF2 DNA binding sites regulate myogenin expression (15, 16) but not MyoD expression (17) during embryogenesis.
Insight into the roles of the MRFs has been gained from gene knockout studies in mice. Skeletal muscle development proceeded normally in homozygous null mice missing either MyoD (18) or myf-5 (19) , but in double homozygous mice lacking both, myoblasts did not form (20) . Mice lacking myogenin produced normal myoblast cells but displayed a marked reduction in secondary myofibers (21) (22) (23) . Taken together these results indicate that MyoD and myf-5 play a role in the determination of skeletal muscle and that myogenin plays an essential in vivo role in the terminal differentiation of secondary muscle fibers.
An essential role for D-MEF2 in the development of cardiac, skeletal, and smooth muscle has been demonstrated by the deficiency of these tissues in Drosophila lacking the single D-mef2 gene (24 -26) . During murine somitogenesis, MEF2C is the first MEF2 factor to be expressed in the somite on day 9, just after expression of myogenin (27, 28) . Mice lacking MEF2C die around embryonic day 10 because of a defect in cardiac looping, whereas mice lacking MEF2B are viable and develop normally.
A dominant-negative form of MEF2A inhibits the differentiation of myoblast cells, indicating that the trans-activation function of MEF2 proteins is essential for skeletal musclespecific gene expression (29) . Although it is believed that MEF2 factors are important for amplifying and maintaining the skeletal myogenic program, the specific MEF2 family member involved and whether MEF2 family members are sufficient to induce myogenesis in mammalian cells is unclear. One study (1) demonstrated that MEF2A induced skeletal muscle development in fibroblasts, whereas another study (3) found that MEF2A did not, although MRF expression could be activated (24) . In contrast, D-MEF2 activated the expression of skeletal muscle-specific genes when overexpressed at a particular stage of development in Drosophila ectoderm (30) .
P19 cells are an alternative system for studying early embryonic events (31) . Upon cellular aggregation, P19 cells undergo differentiation that emulates the biochemical and morphological events of early embryonic development (32, 33). Aggregation of P19 cells with Me 2 SO results in the development of cardiac and skeletal muscle along with other mesodermal and endodermal cell types (34) . These cardiocytes first appear at day 6 following Me 2 SO treatment and express cardiac-specific transcription factors, including GATA-4, Nkx2-5, and MEF2C (35, 36) . P19 cells treated with Me 2 SO differentiate into skeletal muscle by day 9 of differentiation and express MyoD (37) . The development of skeletal and cardiac muscle in P19 cells is regulated by unknown components in the fetal calf serum (38 (36, 40) . 2 Each of the three high expressing P19[MEF2C] cell lines behaved similarly, and all experiments reported were performed at least twice with at least two of these cell lines with similar results.
Differentiation was initiated by plating 5 ϫ 10 5 cells into 60-mm bacterial dishes in the presence of 0.8% Me 2 SO. Cells were cultured as aggregates for 4 days, plated in tissue culture dishes, and harvested for RNA or fixed for immunofluorescence at the time indicated. The fetal calf serum used in the experiments presented in this manuscript did not support the differentiation of P19 cells into skeletal muscle (38) .
Immunofluorescence-P19 and P19[MEF2C] cells were plated on day 4 of differentiation onto gelatin-coated coverslips. For identifying myosin heavy chain (42) , cells were fixed in methanol at Ϫ20°C and reacted with antibody as described (40) . For identifying myogenin, 50 l of the monoclonal antibody F5D supernatant (43) was incubated overnight at 4°C with cells that had been fixed for 1 h at room temperature with Lana's fixative (4% paraformaldehyde, 14% v/v saturated picric acid, 125 mM sodium phosphate). After three 5-min washes in phosphatebuffered saline, cells were incubated for 30 min in 50 l of phosphatebuffered saline with 1 l of goat anti-mouse IgG(HϩL) Cy3-linked antibody (Jackson Immunoresearch Laboratories, West Grove, PA). Immunofluorescence was visualized with a Zeiss Axioskop microscope; images were captured with a Sony 3CCD color video camera, processed using Northern Exposure, Adobe Photoshop, and Corel Draw software, and printed with a dye sublimation phaser 450 Tektronic printer.
Northern Blot Analysis-Total RNA was isolated by the lithium chloride/urea extraction method, and 6 g were examined by Northern blot analysis as described previously (40) . The probes used were: a 600-base pair PstI fragment from the human cardiac ␣-actin last exon (44), a 1.8-kb EcoRI fragment from the mouse MyoD cDNA (6), a 695-base pair EcoRI/PstI fragment from the rat myogenin cDNA (10), a 1.5-kb HindIII/XbaI fragment of MEF2C cDNA (45), a 1.55-kb XhoI/ BamHI fragment of MEF2A cDNA (46), a 1.55-kb XhoI/BamHI fragment of MEF2B cDNA (47) , and a 1.5-kb XhoI/BamHI fragment of MEF2D cDNA (48) . Northern blots were visualized with a Molecular Dynamics PhosphorImager SI and quantitated with ImageQuant software. Averages and standard errors (S.E.) were calculated and reported.
Reverse Transcription Polymerase Chain Reaction-RT-PCR was performed as described previously (36) . A titration of the first strand reaction was performed to ensure that the PCR reaction was analyzed in the linear range. Southern blot analysis was performed on RT-PCR products with a probe from the corresponding cDNA. Negative controls included performing RT-PCR experiments in the absence of RNA, of first strand, and of Superscript II RNase H Ϫ reverse transcriptase. The following pairs of primers were used: 5Ј-tccatccacgtcggccaggct-3Ј and 5Ј-gtagggctcaaccacagcagt-3Ј for tubulin with an annealing temperature of 61°C and 5Ј-gactccccactccccattcacata-3Ј and 5Ј-ggcggcagctttacaaacaacaca-3Ј for myogenin (10) , with an annealing temperature of 55°C.
Western Blot Analysis-Myosin was harvested by the method of Burridge and Bray (49) from cultures at various time points as indicated. The second dialysis step was omitted. Total protein concentration of the myosin extract was measured by the Bio-Rad protein assay (Bio-Rad). Samples (5 g) were separated by electrophoresis on a 7% SDS-polyacrylamide gel, transferred to nitrocellulose, and probed with one of the following mouse monoclonal antibody supernatants: anti-MHC antibody, MF20 (reacts with all forms), at a 1:6000 dilution (42); anti-fast embryonic MHC antibody, 47a, at a 1:500 dilution (50); antineonatal fast, BF-35 (reacts with IIA and IIB), at a 1:10 dilution (51); anti-neonatal slow, 10D10, at a 1:10 dilution (50); and anti-MHC IIB, IIX, 212F, at a 1:10 dilution (50). Anti-mouse IgG, horseradish peroxidase-linked whole antibody (Amersham Pharmacia Biotech) was used as a secondary antibody at a 1:10,000 dilution, and the reaction was visualized using the ECL Western blotting reagent system (Amersham Pharmacia Biotech) and autoradiography.
RESULTS

Myogenin, but Not MyoD, Up-regulates MEF2C Expression-
Several studies have shown differences in the abilities of each of the MRFs to transactivate promoters and to activate endogenous genes. However, the functional significance of these results has not been clearly defined (52) (53) (54) (55) (56) (57) (58) (59) (60) . To determine which MEF2 family members are involved in the regulatory loop with the MRFs, P19[MyoD] (40) and P19[Mgn] cell lines were differentiated and examined for their ability to activate the expression of MEF2 family members.
Northern blots were prepared using RNA from P19[MyoD] and P19 [Mgn] cell lines on day 6 of differentiation in the presence of Me 2 SO. As shown previously (40), 2 both MyoD and myogenin required cellular aggregation to initiate myogenesis. MyoD and myogenin did not cross-activate each other's expression to high levels when compared with their exogenous expression levels (Fig. 1, A and B) . Therefore, P19[MyoD] and P19[Mgn] cells express predominantly one MRF or the other and can be used to study differences in target gene specificity for MyoD and myogenin. MEF2C expression levels (Fig. 1C) paralleled the levels of myogenin (Fig. 1A) and not MyoD ( (Fig. 2) , including embryonic fast, neonatal fast, neonatal slow, and adult fast IIB and IIX. Although a doublet of MHC neonatal slow (Fig. 2D) SO and examined on day 9 by phase contrast microscopy and immunofluorescence with antibodies directed against myogenin and myosin heavy chain (Fig. 3) . Bipolar skeletal myocytes were visible by phase contrast microscopy on day 9 in P19[MEF2C] cultures (Fig. 3D) but not in control cultures (Fig.  3A) . In agreement with the cellular morphology, P19[MEF2C] cultures contained cells that expressed myogenin protein in the nuclei of the bipolar skeletal myocytes (Fig. 3E) . In contrast, P19 control cells did not differentiate into skeletal muscle under the serum conditions used for these experiments, shown by the lack of cells expressing myogenin (Fig. 3B) . These results were confirmed by staining for the presence of myosin heavy chain by immunoreaction with MF20 (42) . MF20 reacts with myosin heavy chain present in both cardiac and skeletal muscle, and these two cell types can be distinguished by their morphology (37) . As expected, P19[MEF2C] cultures contained bipolar skeletal myocytes (Fig. 3F) , whereas P19 control-transfected cells contained only cardiac myocytes (Fig. 3C) . The The conditions required and the extent of differentiation into skeletal muscle were quantitated by counting myogenin and MF20-positive cells under each culture condition. The development of substantial numbers of skeletal myocytes (5-6% of total cells) required MEF2C expression and nine days of differentiation after aggregation with Me 2 SO (Fig. 4) . The number of MF20 positive cells is slightly lower than the number of myogenin-positive cells. The number of myocytes that reacted with MF20 may be an underestimate because only bipolar myocytes were counted. Alternatively, the number could be lower because of a slightly earlier expression of myogenin compared with myosin heavy chain.
MEF2C Expression Results in the Up-regulation of Myogenin
Expression-Northern blot analysis was used to examine the expression of muscle-specific genes. Total RNA from P19 and P19[MEF2C] cultures was harvested on day 6 and day 9 after aggregation with Me 2 SO. Transfected MEF2C transcripts were expressed in P19[MEF2C] cells (Fig. 5A, lanes 4 -6) but not in P19 control cells (Fig. 5A, lanes 1-3) . Interestingly, the expression of exogenous MEF2C transcripts seemed to result in the up-regulation of endogenous MEF2C expression. The expression levels of MEF2A, MEF2B, and MEF2D were very low and did not appear to change in any of the conditions examined (data not shown). The formation of MEF2C-induced skeletal muscle was demonstrated by the expression of myogenin on day 9 in P19[MEF2C] cells but not in P19 control cells (Fig. 5C,  lane 6 compared with 3) . Low levels of MyoD were barely detectable in MEF2C-induced muscle (data not shown). Myf-5 and MRF4 expression were not detected under these conditions (data not shown). Aggregation activated cardiac ␣-actin expression by day 6 in both P19[MEF2C] and P19 cells, indicating the formation of cardiac muscle in both populations (Fig. 5B, lanes  2 and 5) . The level of cardiac ␣-actin expression appears lower in P19[MEF2C] cultures compared with P19 cultures on day 6 (Fig. 5B, lanes 2 and 5) , however this result was variable. Thus, in agreement with the immunofluorescent staining, the Northern blot analysis results support the observation that MEF2C initiates skeletal muscle development.
Because MEF2C is known to act synergistically with the MRFs, semi-quantitative RT-PCR was used to determine MRF expression levels under each condition. Substantial expression of myogenin was observed only in day 9 P19[MEF2C] cultures treated with Me 2 SO (Fig. 6A) , with an average of 130 Ϯ 30-fold over background levels (n ϭ 4). Similarly, increased levels of MyoD were observed only in day 9 P19[MEF2C] cultures treated with Me 2 SO (Fig. 6B ) with an average of 5 Ϯ 1-fold over background levels (n ϭ 4). Therefore, myogenin expression was activated an average of 26-fold more efficiently than MyoD expression. The low levels of MyoD expression detected in P19 and P19[MEF2C] cultures (Fig. 6B, lanes 1-5) were not present in the negative control RT-PCR reactions performed (data not shown). No evidence of increased levels of MyoD or myogenin was found in P19 control cells treated with Me 2 SO (Fig. 6, A  and B, compare lanes 1, 3, and 5) . Therefore, these results show that MEF2C up-regulates the expression of myogenin considerably more efficiently than that of MyoD.
DISCUSSION
Although, the presence of a regulatory loop between the MRFs and MEF2 families has been shown previously (14 -16), the MEF2 family member involved in this regulation was not identified. Our results show that, whereas both MyoD and myogenin induced skeletal myogenesis in aggregated P19 cells, myogenin, and not MyoD, up-regulated the expression of MEF2C during differentiation. Because MEF2A, -B, and -D expression levels remained unchanged, the ability of MEF2C to trigger skeletal muscle was examined. MEF2C initiated skeletal myogenesis in P19 cells aggregated with Me 2 SO. During this process, myogenin expression was up-regulated to a far greater extent than MyoD. Taken together, our results support the presence of a positive regulatory loop between the MEF2 family and the MRFs and indicate that MEF2C and myogenin, but not MyoD or MEF2A, -B, or -D, participate in this loop in differentiating stem cells.
In the murine embryo, MEF2C is expressed shortly after myogenin on day 8.5 (27) . Our finding that myogenin and MEF2C up-regulate each other's expression in P19 cells is consistent with the timing of their expression during embryogenesis. The presence of a positive regulatory loop could enhance the expression of both myogenin and MEF2C in the somites.
Similar to MyoD and myogenin, cellular aggregation was required for the full activity of MEF2C. It is likely that proteins expressed as a result of cellular aggregation regulate MEF2C activity. The lack of up-regulation of MRF expression during the cellular aggregation of control cells suggests that MEF2C may not be simply acting synergistically to amplify low levels of these tissue-restricted transcription factors. Our results agree with the finding that ectopic expression of MEF2 in Drosophila epidermis activates the expression of skeletal muscle genes (30) . This activation was found to be stage-dependent, suggesting that a factor is expressed in Drosophila epidermis that can regulate MEF2C function. Factors that regulate MEF2C may be other transcription factors, kinases, or phosphatases. MEF2C can be regulated by phosphorylation events because of interactions with casein kinase-II (61), mitogen-activated protein kinase p38 (62) (63) (64) , and extracellular signal-regulated kinase 5 (65) . These factors are candidates for regulating MEF2C-induced skeletal myogenesis.
The difference between the results reported here in P19 cells and the contradictory results from studies in fibroblasts is probably because of the expression of the appropriate regulatory molecules in aggregated P19 cells, which may or may not be expressed in fibroblasts. Because P19[MRF] cells produce abundant skeletal muscle (Ͼ30%) and P19[MEF2C] cells produce only moderate amounts of skeletal muscle (Ͻ10%), our results suggest that MyoD is regulated by factors expressed in a larger proportion of the total cell population than factors regulating MEF2C. These results agree with the finding that MyoD can readily initiate myogenesis in fibroblasts.
The use of serum that does not support Me 2 SO-induced skeletal myogenesis in P19 cells may contribute to the ability of MEF2C to function in P19 cells. The exact mechanism by which factors in serum regulate P19 cell myogenesis is unknown (38) . Because MEF2C is known to bind MEF2 sites and activate skeletal muscle-specific promoters, it is likely that MEF2C is functioning in a similar manner in P19 cells. However, MEF2C expression may be promoting myogenesis by activating the expression of other factors involved in myogenesis or cooperating with existing factors. Alternatively, it is possible that the overexpression of MEF2C may lead to myogenesis by sequestering negative regulatory elements.
The phenotypes of MRF knockout mice clearly indicate that MRFs have distinct biological roles in controlling skeletal muscle development. However, the mechanisms that define these differences are still poorly understood. In fibroblasts, MyoD and myogenin tend to cross-activate each other's expression, making it difficult to determine their specific functions (59, 66 -69) . Nevertheless, several studies have shown differences in the ability of MRFs to transactivate both exogenous (52, 54, 57, 70) and endogenous promoters (60) . In the latter experiment, it was shown in fibroblasts that MyoD was 10-fold more efficient than myogenin in activating genes located in regions of transcriptionally silent chromatin. Our results in P19 cells indicate that myogenin was more proficient in activating endogenous MEF2C gene expression than MyoD. The role of chromatin modeling during myogenesis in P19 cells remains to be determined.
Our finding that MHC isoforms were not differentially regulated agrees with previous results, which show no correlation between the expression of MRFs and adult muscle transcripts, like MHC, in mouse muscle cell lines (67, 70, 71) . In contrast to the results obtained in tissue culture, myogenin is expressed at high levels in slow muscle fibers, and MyoD is selectively accumulated in adult rat fast muscle fibers (72) . Because MRFs act via E-box elements, further experiments are required to determine the mechanism by which some E-boxes are differentially regulated by MyoD and myogenin, whereas other E-boxes are not. It seems likely that the N-and C-terminal regions of the MRFs are involved, as shown previously for the differential activation of exogenous promoters (41, 52, 56) . These domains could interact with other factors that may be involved in determining specificity.
In summary, examining the ability of transcription factors to modulate the developmental potential of P19 cells provides a powerful tool for subsequent analysis of the mechanisms involved. Using this system, we have shown that MEF2C and myogenin induce myogenesis and participate in a positive regulatory loop in P19 cells.
